Inventiva S.A. (IVA)Healthcare | Biotechnology | Daix, France | NasdaqGM
5.67 USD
+0.04
(0.710%)
⇧
(April 17, 2026, 4 p.m.
EDT)
After hours: 5.66 -0.01 (-0.010%) ⇩ (April 17, 2026, 7:39 p.m. EDT) Short-term: ★★☆☆☆ | Long-term: ★☆☆☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 18, 2026, 11:40 p.m. EDT
Inventiva (IVA) is a speculative deep-value biotech play with a 'Strong Buy' analyst consensus driven by a massive price-to-target upside (>150%), yet the short-term forecast model signals negative momentum (-0.48% predicted change) and the fundamentals are deteriorating with -89.9% revenue growth, resulting in a sell signal for active traders and a weak long-term hold rating due to unsustainable cash burn. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.134410 |
| MSTL | 0.134914 |
| AutoETS | 0.134983 |
| AutoTheta | 0.141790 |
Forecast horizon: 45 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 50% |
| H-stat | 4.03 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.691 |
| Excess Kurtosis | -0.33 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Revenue per Share | 0.036 |
| Market Cap | 1,177,363,712 |
| Forward P/E | -4.46 |
| Beta | 0.95 |
| Website | https://inventivapharma.com |
| Attribute | Value |
|---|---|
| 52 Week Change | 0.59269667 |
| Address1 | 50 rue de Dijon |
| All Time High | 19.064 |
| All Time Low | 1.53 |
| Ask | 5.73 |
| Ask Size | 1 |
| Average Analyst Rating | 1.2 - Strong Buy |
| Average Daily Volume10 Day | 640,230 |
| Average Daily Volume3 Month | 449,400 |
| Average Volume | 449,400 |
| Average Volume10Days | 640,230 |
| Beta | 0.948 |
| Bid | 5.63 |
| Bid Size | 1 |
| Book Value | -0.07332096 |
| City | Daix |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | France |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 5.67 |
| Current Ratio | 3.159 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 5.79 |
| Day Low | 5.645 |
| Display Name | Inventiva |
| Earnings Call Timestamp End | 1,774,987,200 |
| Earnings Call Timestamp Start | 1,774,987,200 |
| Earnings Timestamp | 1,774,900,800 |
| Earnings Timestamp End | 1,774,900,800 |
| Earnings Timestamp Start | 1,774,900,800 |
| Ebitda | -132,497,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -9.878 |
| Enterprise To Revenue | 193.574 |
| Enterprise Value | 1,308,752,384 |
| Eps Current Year | -0.82033 |
| Eps Forward | -1.27157 |
| Eps Trailing Twelve Months | -2.24 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 6.008 |
| Fifty Day Average Change | -0.33799982 |
| Fifty Day Average Change Percent | -0.056258295 |
| Fifty Two Week Change Percent | 59.26967 |
| Fifty Two Week High | 7.983 |
| Fifty Two Week High Change | -2.3129997 |
| Fifty Two Week High Change Percent | -0.28974068 |
| Fifty Two Week Low | 2.854 |
| Fifty Two Week Low Change | 2.816 |
| Fifty Two Week Low Change Percent | 0.98668534 |
| Fifty Two Week Range | 2.854 - 7.983 |
| Financial Currency | EUR |
| First Trade Date Milliseconds | 1,594,387,800,000 |
| Float Shares | 122,208,847 |
| Forward Eps | -1.27157 |
| Forward P E | -4.459055 |
| Free Cashflow | -200,711,632 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 69 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.99675006 |
| Gross Profits | 6,739,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.0 |
| Held Percent Institutions | 0.25537002 |
| Implied Shares Outstanding | 207,647,924 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,020-07-10 |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. The company develops Lanifibranor, a novel pan-peroxisome proliferator-activated receptor agonist that is in the NATiV3 Phase 3 clinical trial to treat adult patients with MASH; and Odiparcil for the treatment of patients with mucopolysaccharidoses. It also develops TGF-ß, a pre-clinical program for the treatment of idiopathic pulmonary fibrosis. The company was incorporated in 2011 and is headquartered in Daix, France. |
| Long Name | Inventiva S.A. |
| Market | us_market |
| Market Cap | 1,177,363,712 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_273516426 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -354,137,984 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 1,179,017,209 |
| Number Of Analyst Opinions | 13 |
| Open | 5.695 |
| Operating Cashflow | -104,884,000 |
| Operating Margins | -67.10686 |
| Payout Ratio | 0.0 |
| Phone | 33 3 80 44 75 00 |
| Post Market Change | -0.010000229 |
| Post Market Change Percent | -0.17637087 |
| Post Market Price | 5.66 |
| Post Market Time | 1,776,469,186 |
| Previous Close | 5.63 |
| Price Eps Current Year | -6.9118524 |
| Price Hint | 2 |
| Price To Book | -77.33123 |
| Price To Sales Trailing12 Months | 174.14047 |
| Profit Margins | 0.0 |
| Quick Ratio | 1.408 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.15385 |
| Region | US |
| Regular Market Change | 0.04 |
| Regular Market Change Percent | 0.710479 |
| Regular Market Day High | 5.79 |
| Regular Market Day Low | 5.645 |
| Regular Market Day Range | 5.645 - 5.79 |
| Regular Market Open | 5.695 |
| Regular Market Previous Close | 5.63 |
| Regular Market Price | 5.67 |
| Regular Market Time | 1,776,456,000 |
| Regular Market Volume | 446,889 |
| Return On Assets | -0.45079 |
| Revenue Growth | -0.899 |
| Revenue Per Share | 0.036 |
| Sand P52 Week Change | 0.38150132 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 207,647,924 |
| Shares Percent Shares Out | 0.0022 |
| Shares Short | 449,688 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 549,755 |
| Short Name | Inventiva S.A. - American Depos |
| Short Percent Of Float | 0.0023 |
| Short Ratio | 1.56 |
| Source Interval | 15 |
| Symbol | IVA |
| Target High Price | 26.0 |
| Target Low Price | 8.8 |
| Target Mean Price | 15.12623 |
| Target Median Price | 13.0 |
| Total Cash | 99,839,000 |
| Total Cash Per Share | 0.481 |
| Total Debt | 230,890,000 |
| Total Revenue | 6,761,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -2.24 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 5.05413 |
| Two Hundred Day Average Change | 0.61587 |
| Two Hundred Day Average Change Percent | 0.1218548 |
| Type Disp | Equity |
| Volume | 446,889 |
| Website | https://inventivapharma.com |
| Zip | 21,121 |